Fundraising Fox
/Companies
Sign in

Modulate Bio

Allston, US · Founded 2023 · Delaware corporation · 4 employees on LinkedIn · 3 known investors

Find your way into Modulate Bio

Each arrow is one introduction. Sign up to fill in the first one.

235 people can intro you to Dario

Ask Anthony Uzzo to introduce you to Dario Doller

You →Anthony · together at Neurogen Corporation →Dario

Sign up to find every way you can get introduced to Modulate Bio

  • Your email: who you already know at Modulate Bio, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Modulate Bio team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.

BiotechDeep TechHealthtech

Founders & leadership

Modulate Bio was founded in 2023 by Dario Doller and Kevin Hodgetts.

DDDario Doller
Dario DollerCo-founder · Chief Scientific Officer (CSO)Dario Doller is a medicinal chemist with 30 years of experience in pharmaceutical drug discovery across CNS targets. He has contributed to the development of Vorapaxar and four additional FDA-approved or clinical-stage drugs, and co-edited two volumes on allosterism and CNS drug discovery.
KHKevin Hodgetts
Kevin HodgettsFounding Lab / Co-founder
AT
Andrew ThomsonNamed on SEC filing
MB
Mitchell Buckley

Investors · 3

Palo Santo VClisted by Palo Santo VC

How we know: Palo Santo VC's portfolio page · Not right? Tell us

Healthspan CapitalreportedOxford · $5K

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$785.3K disclosed across 1 round · 2024

▶$785.3KraisedApr 2026 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin HodgettsPromoter
  • Dario DollerExecutive Officer, Director, Promoter
  • Andrew ThomsonExecutive Officer, Director, Promoter
Offering amount
$1M
Amount sold
$785.3K
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 8

Liberate BioLiberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
ModulightModulight develops a platform to treat severe neurological diseases through scientific innovation and clinical expertise.
Emulate BioEmulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research. It serves life sciences and pharmaceutical researchers and provides installation, training, and validated protocols for Organ-Chip experiments.
CreateCREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies. The company focuses on RNA therapeutics and immune engineering for cancer, autoimmune disease, and transplant rejection applications.
Modulari-TModulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Modulo BioModulo is a biotech company focused on the neuroimmune system, developing treatments for brain and central nervous system disorders. It uses multiple neurobiology models and computational biology to study neuroimmune mechanisms and discover new therapies for patients affected by neurological disease.

Companies working in the same space as Modulate Bio.

Frequently asked questions

What does Modulate Bio do?
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
Who founded Modulate Bio?
Modulate Bio was founded by Dario Doller, Kevin Hodgetts in 2023.
Who are Modulate Bio's investors?
Modulate Bio's investors include Pillar VC, Palo Santo VC, Healthspan Capital.
How much funding has Modulate Bio raised?
Modulate Bio has disclosed $785.3K raised across 1 round.
Where is Modulate Bio headquartered?
Modulate Bio is headquartered in Allston, US.